文献速递帕金森病与运动障碍

社区神经科医生姑息治疗教育与远程医疗支持对帕金森病患者及家属结局的影响

Patient and Family Outcomes of Community Neurologist Palliative Education and Telehealth Support in Parkinson Disease.
PubMed 文献 · JAMA Neurol · 2024-01-01

这项实用型阶梯楔形比较效果试验纳入19家社区神经科诊所的359例帕金森病及相关疾病患者,评估神经科医生接受姑息治疗教育及远程姑息团队支持的效果。6个月时干预组生活质量改善优于常规组,照护者负担无显著差异,预先医疗指示完成率更高。总体效应较小,提示干预和实施有待改进。

要点

  • 社区神经科医生姑息治疗教育联合远程团队支持可改善患者6个月生活质量。
  • 干预组与常规组照护者负担无显著差异。
  • 干预组预先医疗指示完成率高于常规组。

核心结论

  • 社区神经科医生接受姑息治疗教育并通过远程医疗获得团队支持是可行的,可能改善生活质量和预先医疗照护规划。
  • 总体治疗效应较小,提示有机会改进干预和实施。

研究设计与样本

  • 实用型阶梯楔形比较效果试验,纳入2017年3月8日至2020年12月31日期间19家社区神经科诊所的患者,这些诊所由2个学术中心的姑息治疗团队支持。
  • 共转诊612例帕金森病及相关疾病患者,排除253例后,359例患者(233例男性[64.9%];平均[SD]年龄74.0[8.8]岁)和300名照护者入组。
  • 患者根据其社区神经科医生被随机分配开始干预的时间接受常规照护或干预。
  • 数据分析时间为2021年1月至2023年9月。

主要发现

  • 6个月时,干预组生活质量(QOL-AD评分)为0.09(95%CI,-0.63至0.82),常规组为-0.88(95%CI,-1.62至-0.13);治疗效应估计值为0.97(95%CI,0.07-1.86;P=0.03)。
  • 6个月时,照护者负担(Zarit负担访谈评分)干预组为1.19(95%CI,0.16至2.23),常规组为0.55(95%CI,-0.44至1.54);治疗效应估计值为0.64(95%CI,-0.62至1.90;P=0.32),无显著差异。
  • 在基线无预先医疗指示者中,干预组完成预先医疗指示的比例为50%(19/38),常规组为19%(6/31);P=0.008。
  • 其他结局无差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 总体治疗效应较小,提示有机会改进干预和实施。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Parkinson disease and related disorders (PDRD) are the fastest growing neurodegenerative illness in terms of prevalence and mortality. As evidence builds to support palliative care (PC) for PDRD, studies are needed to guide implementation. OBJECTIVE: To determine whether PC training for neurologists and remote access to a PC team improves outcomes in patients with PDRD in community settings. DESIGN, SETTING, AND PARTICIPANTS: This pragmatic, stepped-wedge comparative effectiveness trial enrolled and observed participants from 19 community neurology practices supported by PC teams at 2 academic centers from March 8, 2017, to December 31, 2020. Participants were eligible if they had PDRD and moderate to high PC needs. A total of 612 persons with PDRD were referred; 253 were excluded. Patients were excluded if they had another diagnosis meriting PC, were receiving PC, or were unable or unwilling to follow study procedures. Patients received usual care or the intervention based on when their community neurologist was randomized to start the intervention. Data were analyzed from January 2021 to September 2023. INTERVENTION: The intervention included (1) PC education for community neurologists and (2) team-based PC support via telehealth. MAIN OUTCOMES AND MEASURES: The primary outcomes were differences at 6 months in patient quality of life (QOL; measured by the Quality of Life in Alzheimer Disease Scale [QOL-AD]) and caregiver burden (Zarit Burden Interview) between the intervention and usual care. RESULTS: A total of 359 patients with PDRD (233 men [64.9%]; mean [SD] age, 74.0 [8.8] years) and 300 caregivers were enrolled. At 6 months, compared with usual care, participants receiving the intervention had better QOL (QOL-AD score, 0.09 [95% CI, -0.63 to 0.82] vs -0.88 [95% CI, -1.62 to -0.13]; treatment effect estimate, 0.97; 95% CI, 0.07-1.86; P = .03). No significant difference was observed in caregiver burden (Zarit Burden Interview score, 1.19 [95% CI, 0.16 to 2.23] vs 0.55 [95%, -0.44 to 1.54]; treatment effect estimate, 0.64; 95% CI, -0.62 to 1.90; P = .32). Advance directive completion was higher under the intervention (19 of 38 [50%] vs 6 of 31 [19%] among those without directives at the beginning of the study; P = .008). There were no differences in other outcomes. CONCLUSIONS AND RELEVANCE: PC education for community neurologists and provision of team-based PC via telehealth is feasible and may improve QOL and advance care planning. Overall treatment effects were small and suggest opportunities to improve both the intervention and implementation. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03076671.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Kluger BM, Katz M, Galifianakis NB, et al. Patient and Family Outcomes of Community Neurologist Palliative Education and Telehealth Support in Parkinson Disease. JAMA Neurol. 2024. PMID: 37955923. doi:10.1001/jamaneurol.2023.4260

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。